Growing SaMD VoxNeuro is a commercial-stage Software-as-a-Medical-Device company specializing in brain health assessment, with recent equity funding of 3.4 million to scale its brain performance software across US clinics. Target clinics and hospital networks focusing on cognitive health, concussion management, and neuro-rehabilitation present a clear expansion path.

Clinical Partnerships Strategic partnerships with Boston University and potential ties to medical research initiatives (e.g., mild traumatic brain injury and Alzheimer's research) indicate a track record of collaboration with major academic institutions. Leverage these relationships to approach affiliated clinics, researchers, and patient cohorts for trials and deployment.

Public-Sector Access A Health Canada Class II designation for CHAMP signals regulatory credibility and potential interest from government-funded health programs and national clinics. Explore opportunities with public health systems and Veterans Affairs-like programs that need objective cognitive assessment tools.

Fleet Growth Opportunity Recent financing aimed at accelerating scaling suggests readiness to expand clinic installations and service networks in the US. Prioritize enterprise sales efforts toward multi-site healthcare providers, hospital systems, and telemedicine-enabled clinics seeking standardized cognitive assessments.

Evidence & Validation Active clinical studies with academic partners imply growing evidence for diagnostic accuracy in outpatient settings. Use forthcoming study results as proof points to drive trials, reimbursements, and payer talks, appealing to clinics requiring validated SaaMD solutions.